These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 12269713)

  • 41. Bone Marrow Concentrate (BMC) Therapy in Musculoskeletal Disorders: Evidence-Based Policy Position Statement of American Society of Interventional Pain Physicians (ASIPP).
    Manchikanti L; Centeno CJ; Atluri S; Albers SL; Shapiro S; Malanga GA; Abd-Elsayed A; Jerome M; Hirsch JA; Kaye AD; Aydin SM; Beall D; Buford D; Borg-Stein J; Buenaventura RM; Cabaret JA; Calodney AK; Candido KD; Cartier C; Latchaw R; Diwan S; Dodson E; Fausel Z; Fredericson M; Gharibo CG; Gupta M; Kaye AM; Knezevic NN; Kosanovic R; Lucas M; Manchikanti MV; Mason RA; Mautner K; Murala S; Navani A; Pampati V; Pastoriza S; Pasupuleti R; Philip C; Sanapati MR; Sand T; Shah RV; Soin A; Stemper I; Wargo BW; Hernigou P
    Pain Physician; 2020 Mar; 23(2):E85-E131. PubMed ID: 32214287
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The potential impact of usp general chapter <797> on procedures and requirements for the preparation of sterile radiopharmaceuticals.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):21N-6N. PubMed ID: 15181115
    [No Abstract]   [Full Text] [Related]  

  • 43. Compounding parenteral nutrition: reducing the risks.
    Curtis C; Sacks GS
    Nutr Clin Pract; 2009; 24(4):441-6. PubMed ID: 19605798
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 45. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness--FDA. Proposed rule.
    Fed Regist; 1998 Oct; 63(195):54082-9. PubMed ID: 10185826
    [TBL] [Abstract][Full Text] [Related]  

  • 46. How gaps in regulation of compounding pharmacy set the stage for a multistate fungal meningitis outbreak.
    Teshome BF; Reveles KR; Lee GC; Ryan L; Frei CR
    J Am Pharm Assoc (2003); 2014; 54(4):441-5. PubMed ID: 25063265
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Revocation of regulation on positron emission tomography drug products--FDA. Final rule; revocation.
    Fed Regist; 1997 Dec; 62(244):66522. PubMed ID: 10179303
    [TBL] [Abstract][Full Text] [Related]  

  • 48. International Academy of Compounding Pharmacists' Legislative Regulatory Update: Take Action! Stop the U.S. Food and Drug Administration's Misguided Veterinary Guidance.
    Miller DG
    Int J Pharm Compd; 2015; 19(6):449-50. PubMed ID: 26891558
    [No Abstract]   [Full Text] [Related]  

  • 49. Establishing benchmark rates of microbial and bacterial endotoxin contamination for radiopharmaceuticals compounded in commercial nuclear pharmacy settings.
    Weatherman KD; Augustine S; Christoff J; Galbraith W
    Int J Pharm Compd; 2013; 17(2):168-74. PubMed ID: 23696179
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Instrumentation and radiopharmaceutical validation.
    Zigler SS
    Q J Nucl Med Mol Imaging; 2009 Aug; 53(4):402-10. PubMed ID: 19834450
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radiopharmaceutical regulation and Food and Drug Administration policy.
    Rotman M; Laven D; Levine G
    Semin Nucl Med; 1996 Apr; 26(2):96-106. PubMed ID: 8723504
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 May; 64(94):26657-70. PubMed ID: 10558516
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Extemporaneous compounding: a return to regulatory limbo?
    Winckler SC
    J Pain Palliat Care Pharmacother; 2002; 16(4):71-8. PubMed ID: 14635828
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Distinguishing between compounding facilities and the development of the 503B bulk drug substance list.
    Gianturco SL; Mattingly AN
    J Am Pharm Assoc (2003); 2021; 61(1):e8-e11. PubMed ID: 32713748
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Evolution of 21 CFR Parts 210 & 211 for Drug Compounders: AN UNSPOKEN OPPORTUNITY FOR PHARMACISTS.
    Parks KC; Bernard B; Cogdill CB
    Int J Pharm Compd; 2015; 19(5):377-80. PubMed ID: 26775444
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Litigating the legality of compounding: the medical center pharmacy case.
    Gibbs JN
    Int J Pharm Compd; 2008; 12(3):238-41. PubMed ID: 23969713
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Integration of temperature-controlled requirements into pharmacy practice.
    Ziance R; Chandler C; Bishara RH
    J Am Pharm Assoc (2003); 2009; 49(3):e61-7; quiz e68-9. PubMed ID: 19443313
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Compounding for women's health: a compounder's perspective - need, regulations, and future.
    Boomsma D; Lahoud G
    Climacteric; 2021 Feb; 24(1):32-37. PubMed ID: 33135943
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The future of USP monographs for PET drugs.
    Schwarz S; Norenberg J; Berridge M; Dragotakes S; Hung J; Link J; Mason NS; Mattmuller S; Nickel RA; Packard A; Paolino J; Petry N; Ponto J; Quinton TM; Seifert KL; Swanson D; Weiner RE; Zigler S
    J Nucl Med; 2013 Mar; 54(3):472-5. PubMed ID: 23264689
    [No Abstract]   [Full Text] [Related]  

  • 60. PreScription: Comments on the FDA Guidance "Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry".
    Allen LV
    Int J Pharm Compd; 2022; 26(2):92. PubMed ID: 35413006
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.